{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-248772","form_type":"8-K","ticker":"SPRO","cik":"0001701108","company_name":"Spero Therapeutics, Inc.","filed_at":"2022-09-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.702322+00:00","generated_at":"2026-06-23T08:02:38.373703+00:00","sec_items":["1.01","3.02","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Spero licenses tebipenem HBr to GSK for $66M upfront, up to $525M milestones plus tiered royalties","bullets":["GSK gets exclusive license to develop and commercialize oral carbapenem antibiotic tebipenem HBr outside Japan and certain Asian countries.","Spero receives $66M upfront; potential milestones: $150M Phase III delivery, $150M first sale (US/EU), $225M sales milestones up to $1B+.","Tiered royalties low-single to low-double digit increase if net sales exceed $1B.","GSK invests $9M in Spero common stock at ~$1.20805/share (7.45M shares), with lock-up and standstill provisions.","Spero to start a new Phase 3 trial in 2023; closing expected Q4 2022 subject to HSR clearance."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-248772","json":"https://secwatch.observer/filing/0001193125-22-248772.json","markdown":"https://secwatch.observer/filing/0001193125-22-248772.md","text":"https://secwatch.observer/filing/0001193125-22-248772.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1701108/000119312522248772/0001193125-22-248772-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1701108/000119312522248772/d370224d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T08:02:38.373703+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}